Wellington Management Group LLP Buys New Shares in Omeros Co. (NASDAQ:OMER)

Wellington Management Group LLP acquired a new position in Omeros Co. (NASDAQ:OMER - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 76,945 shares of the biopharmaceutical company's stock, valued at approximately $305,000. Wellington Management Group LLP owned approximately 0.13% of Omeros as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently bought and sold shares of OMER. State Street Corp increased its holdings in shares of Omeros by 0.3% in the 3rd quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company's stock valued at $4,867,000 after purchasing an additional 3,839 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Omeros by 4.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 485,035 shares of the biopharmaceutical company's stock worth $1,926,000 after buying an additional 18,454 shares during the period. Bank of New York Mellon Corp increased its holdings in Omeros by 16.6% in the second quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company's stock valued at $887,000 after buying an additional 31,081 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Omeros by 6.1% during the 2nd quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company's stock valued at $454,000 after acquiring an additional 6,435 shares during the period. Finally, HighTower Advisors LLC boosted its stake in shares of Omeros by 7.2% during the 3rd quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company's stock worth $235,000 after acquiring an additional 4,000 shares in the last quarter. Institutional investors and hedge funds own 48.79% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. Rodman & Renshaw initiated coverage on Omeros in a research note on Thursday, November 14th. They issued a "buy" rating and a $9.00 price objective for the company. Needham & Company LLC restated a "hold" rating on shares of Omeros in a research report on Thursday. StockNews.com raised Omeros from a "sell" rating to a "hold" rating in a research note on Wednesday, November 20th. RODMAN&RENSHAW raised shares of Omeros to a "strong-buy" rating in a research note on Thursday, November 14th. Finally, Cantor Fitzgerald restated a "neutral" rating on shares of Omeros in a research report on Thursday, November 14th. Three equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Omeros currently has a consensus rating of "Moderate Buy" and a consensus price target of $9.00.

Omeros Price Performance

OMER traded up $0.07 during trading on Friday, hitting $10.31. The company's stock had a trading volume of 2,506,727 shares, compared to its average volume of 550,411. Omeros Co. has a twelve month low of $2.61 and a twelve month high of $13.60. The firm's 50 day moving average price is $7.09 and its 200-day moving average price is $5.19. The stock has a market cap of $597.46 million, a PE ratio of -4.46 and a beta of 1.97.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.